Protocol Ledger

NCT06260722 · Phase III · ACTIVE NOT RECRUITING

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Interventional Phase III clinical trial protocol NCT06260722 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-21 Enrollment: 1,250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06260722
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06260722
Protocol FieldVerified Registry Value
NCT IdentifierNCT06260722
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1,250 participants (ESTIMATED)
Registered Start Date2024-02-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06260722
Hospital Research SiteLocationSite Profile
Valley Clinical Trials, Inc.Northridge, CAOpen Hospital Dossier ->
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI